文献速递肺外科

早期非小细胞肺癌肺叶特异性淋巴结清扫术后的长期生存结局

Long-term survival outcomes after lobe-specific nodal dissection in patients with early non-small-cell lung cancer.
PubMed 文献 · Eur J Cardiothorac Surg · 2023-01-01

本研究回顾性分析接受肺叶切除术加纵隔淋巴结清扫的c-I、II期非小细胞肺癌(NSCLC)患者,倾向评分匹配后比较肺叶特异性淋巴结清扫(LSD)与系统性淋巴结清扫(SND)的长期结局。中位随访8.4年,438对匹配患者中两组总生存(OS)和无复发病生存(RFS)相似,但LSD组术后5年后预后更佳,且其他疾病累积死亡发生率(CID)更低;c-II期患者中LSD组OS和RFS更差、原发肺癌CID更高。结论认为LSD对早期NSCLC长期生存可接受,但可能不适用于c-II期患者。

要点

  • LSD与SND组OS的HR为0.979(95%CI 0.799-1.199),RFS的HR为0.912(95%CI 0.762-1.092),均相似。
  • LSD组其他疾病CID低于SND组,HR为0.702(95%CI 0.525-0.938)。
  • c-II期患者中LSD组OS和RFS更差、原发肺癌CID更高,LSD可能不适用。

核心结论

  • LSD为早期NSCLC患者提供可接受的长期生存。
  • 但由于原发肺癌死亡风险更高,LSD可能不适用于c-II期NSCLC患者。

研究设计与样本

  • 回顾性分析接受肺叶切除术加纵隔淋巴结清扫的c-I和II期NSCLC患者。
  • 采用倾向评分匹配后比较LSD组与SND组的OS、RFS以及原发肺癌和其他疾病的CID。
  • 中位随访8.4年,倾向评分匹配后纳入438对患者。

主要发现

  • LSD组与SND组OS相似,HR为0.979(95%CI 0.799-1.199)。
  • LSD组与SND组RFS相似,HR为0.912(95%CI 0.762-1.092)。
  • LSD组术后5年后预后优于SND组。
  • 两组原发肺癌CID相似,HR为1.239(95%CI 0.940-1.633)。
  • LSD组其他疾病CID低于SND组,HR为0.702(95%CI 0.525-0.938)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We investigated the long-term outcomes of lobe-specific nodal dissection (LSD) and systematic nodal dissection (SND) in patients with non-small-cell lung cancer (NSCLC). METHODS: Patients with c-stage I and II NSCLC who underwent lobectomy with mediastinal nodal dissection were retrospectively analysed. After propensity score matching, we assessed the overall survival (OS), recurrence-free survival (RFS) and cumulative incidence of death (CID) from primary lung cancer and other diseases. RESULTS: The median follow-up period was 8.4 years. Among 438 propensity score-matched pairs, OS and RFS were similar between the LSD and SND groups [hazard ratio (HR), 0.979; 95% confidence interval (CI), 0.799-1.199; and HR, 0.912; 95% CI, 0.762-1.092, respectively], but the LSD group showed a better prognosis after 5 years postoperatively. CID from primary lung cancer was similar between the 2 groups (HR, 1.239; 95% CI, 0.940-1.633). However, the CID from other diseases was lower in the LSD group than in the SND group (HR, 0.702; 95% CI, 0.525-0.938). According to c-stage, the LSD group tended towards worse OS and RFS, with higher CID from primary lung cancer than the SND group, in patients with c-stage II. CONCLUSIONS: LSD provides acceptable long-term survival for patients with early-stage NSCLC. However, LSD may not be suitable for patients with c-stage II NSCLC due to the higher mortality risk from primary lung cancer.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Kamigaichi A, Aokage K, Ikeno T, et al. Long-term survival outcomes after lobe-specific nodal dissection in patients with early non-small-cell lung cancer. Eur J Cardiothorac Surg. 2023. PMID: 36715610. doi:10.1093/ejcts/ezad016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。